Duchenne Muscular Dystrophy (DMD)

Rare Diseases
6
Pipeline Programs
6
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Satellos Bioscience
Satellos BioscienceTORONTO, Ontario, Canada
1 program
1
SAT-3247Phase 21 trial
Active Trials
NCT06867107Enrolling By Invitation10Est. Aug 2026
Entrada Therapeutics
2 programs
2
ENTR-601-44Phase 1/21 trial
ENTR-601-45Phase 1/21 trial
Active Trials
NCT07037862Recruiting24Est. Mar 2029
NCT07038824Recruiting24Est. Mar 2029
Dyne Therapeutics
1 program
1
DYNE-251Phase 1/21 trial
Active Trials
NCT05524883Active Not Recruiting86Est. Nov 2029
Astellas
AstellasChina - Shenyang
1 program
1
BocidelparPhase 11 trial
Active Trials
NCT04184882Terminated8Est. Sep 2022
Ractigen Therapeutics
Ractigen TherapeuticsChina - Nantong
1 program
1
RAG-18Phase 11 trial
Active Trials
NCT07282652Active Not RecruitingEst. Nov 2026
Pfizer
PfizerNEW YORK, NY
1 program
Activity MonitorN/A1 trial
Active Trials
NCT04254172Terminated2Est. Aug 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Satellos BioscienceSAT-3247
Entrada TherapeuticsENTR-601-45
Entrada TherapeuticsENTR-601-44
Dyne TherapeuticsDYNE-251
Ractigen TherapeuticsRAG-18
AstellasBocidelpar
PfizerActivity Monitor

Clinical Trials (7)

Total enrollment: 154 patients across 7 trials

NCT06867107Satellos BioscienceSAT-3247

A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study

Start: Aug 2025Est. completion: Aug 202610 patients
Phase 2Enrolling By Invitation
NCT07038824Entrada TherapeuticsENTR-601-45

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

Start: Aug 2025Est. completion: Mar 202924 patients
Phase 1/2Recruiting
NCT07037862Entrada TherapeuticsENTR-601-44

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Start: Jun 2025Est. completion: Mar 202924 patients
Phase 1/2Recruiting
NCT05524883Dyne TherapeuticsDYNE-251

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Start: Aug 2022Est. completion: Nov 202986 patients
Phase 1/2Active Not Recruiting
NCT07282652Ractigen TherapeuticsRAG-18

A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy

Start: Dec 2025Est. completion: Nov 2026
Phase 1Active Not Recruiting
NCT04184882AstellasBocidelpar

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Start: Feb 2021Est. completion: Sep 20228 patients
Phase 1Terminated
NCT04254172PfizerActivity Monitor

A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy

Start: Feb 2020Est. completion: Aug 20202 patients
N/ATerminated

Related Jobs in Rare Diseases

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
8h ago
From $130K/yr

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
Somerville, Massachusetts, United States
8h ago

Medical Engagement Manager – Diamyd Medical

Bonesupport
Stockholm, Sweden
Yesterday

Exec. Director, Global Patient Engagement

BioCryst Pharmaceuticals
US_North Carolina_Headquarters
Yesterday

Sr. Director, Regulatory CMC

Genetix Biotherapeutics
Somerville, MA
4d ago
From $270K/yr

Associate Director, Quality Systems

Genetix Biotherapeutics
Somerville, Massachusetts
4d ago
From $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 154 patients
6 companies competing in this space

Related Indications

Cystic Fibrosis(244)Hemophilia A(139)Sickle Cell Disease(64)Fabry Disease(55)Duchenne Muscular Dystrophy(53)Hemophilia B(47)Spinal Muscular Atrophy(34)Phenylketonuria(32)Gaucher Disease(29)Severe Hemophilia A(26)